Abstract:Glycosylation of recombinant therapeutics like monoclonal antibodies (mAbs) is a critical quality attribute. N-glycans in mAbs are known to affect various effector functions, and thereby therapeutic use of such glycoproteins can depend on a particular glycoform profile to achieve desired efficacy. However, there are currently limited options for modulating the glycoform profile, which depend mainly on over-expression or knock-out of glycosyltransferase enzymes that can introduce or eliminate specific glycans but do not allow predictable glycoform modulation over a range of values. In this study, we demonstrate the ability to predictably modulate the glycoform profile of recombinant IgG. Using CRISPR/Cas9, we have engineered nucleotide sugar synthesis pathways in CHO cells expressing recombinant IgG for combinatorial modulation of galactosylation and fucosylation. Knocking out the enzymes UDP-galactose 4'-epimerase (Gale) and GDP-L-fucose synthase (Fx) resulted in ablation of de novo synthesis of UDP-Gal and GDP-Fuc. With Gale knock-out, the array of N-glycans on recombinantly expressed IgG is narrowed to agalactosylated glycans, mainly A2F glycan (89%). In the Gale and Fx double knock-out cell line, agalactosylated and afucosylated A2 glycan is predominant (88%). In the double knock-out cell line, galactosylation and fucosylation was entirely dependent on the salvage pathway, which allowed for modulation of UDP-Gal and GDP-Fuc synthesis and intracellular nucleotide sugar availability by controlling the availability of extracellular galactose and fucose. We demonstrate that the glycoform profile of recombinant IgG can be modulated from containing predominantly agalactosylated and afucosylated glycans to up to 42% and 96% galactosylation and fucosylation, respectively, by extracellular feeding of sugars in a dose-dependent manner. By simply varying the availability of extracellular galactose and/or fucose, galactosylation and fucosylation levels can be simultaneously and independently modulated. In addition to achieving the production of tailored glycoforms, this engineered CHO host platform can cater to the rapid synthesis of variably glycoengineered proteins for evaluation of biological activity.

Model‐based optimization of antibody galactosylation in CHO cell culture

Identifying a robust design space for glycosylation during monoclonal antibody production

Control of IgG glycosylation by in situ and real‐time estimation of specific growth rate of CHO cells cultured in bioreactor

Probabilistic model by Bayesian network for the prediction of antibody glycosylation in perfusion and fed‐batch cell cultures

Modulating antibody N-glycosylation through feed additives using a multi-tiered approach

Engineering nucleotide sugar synthesis pathways for independent and simultaneous modulation of N-glycan galactosylation and fucosylation in CHO cells

Tuning monoclonal antibody galactosylation using Raman spectroscopy‐controlled lactic acid feeding

Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE

Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform

CHO cell productivity improvement by genome-scale modeling and pathway analysis: Application to feed supplements

Population balance modelling captures host cell protein dynamics in CHO cell cultures

Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality

Cell-culture process optimization via model-based predictions of metabolism and protein glycosylation

Dynamic optimization of an integrated cultivation‐aggregation model for mAb production

A metabolic network-based approach for developing feeding strategies for CHO cells to increase monoclonal antibody production

Exploring Metabolic Responses and Pathway Changes in CHO-K1 Cells under Varied Aeration Conditions and Copper Supplementations Using 1H NMR-based Metabolomics

Metabolite profiling of CHO cells: Molecular reflections of bioprocessing effectiveness

Development and validation of a platform reduced intact mass method for process monitoring of monoclonal antibody glycosylation during routine manufacturing

Glycoengineering design options for IgG1 in CHO cells using precise gene editing

Model-Based Optimization of a Fed-Batch Bioreactor for mAb Production Using a Hybridoma Cell Culture

Strategies to improve CHO cell culture performance: Targeted deletion of amino acid catabolism and apoptosis genes paired with growth inhibitor supplementation.